Molecular classification of prostate cancer using curated expression signatures
暂无分享,去创建一个
Hideaki Mizuno | Elke K Markert | Alexei Vazquez | A. Levine | A. Vazquez | E. Markert | H. Mizuno | Arnold J Levine | Hideaki Mizuno
[1] D. Bostwick,et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.
[2] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[3] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[4] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[5] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[6] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[7] Shunyou Wang,et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[9] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[10] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[11] R. Shah,et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.
[12] S. Serrano,et al. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations , 2008, Modern Pathology.
[13] J. Cuzick,et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.
[14] Jun Luo,et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.
[15] P. Nelson,et al. A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.
[16] M. Loda,et al. Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.
[17] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[18] Manuel Serrano,et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.
[19] M. Blasco,et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.
[20] Pier Paolo Pandolfi,et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.
[21] F. Saad,et al. PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.
[22] Jeroen S. van Zon,et al. Direct cell reprogramming is a stochastic process amenable to acceleration , 2009, Nature.
[23] M. Gerstein,et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression , 2010, BMC Medical Genomics.
[24] W. Isaacs,et al. TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.
[25] D. Berney,et al. Duplication of the fusion of TMPRSS 2 to ERG sequences identifies fatal human prostate cancer , 2009 .
[26] A. Levine,et al. Stem cell biology meets p53 , 2009, Nature Biotechnology.
[27] T. Ichisaka,et al. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.
[28] R. Kittles,et al. Association of CD14 variant with prostate cancer in African American men , 2010, The Prostate.
[29] Jaya M Satagopan,et al. TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features , 2010, Modern Pathology.
[30] G. Wahl,et al. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures , 2010, Proceedings of the National Academy of Sciences.
[31] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[32] Sebastián M. Real,et al. E2F1 Regulates Cellular Growth by mTORC1 Signaling , 2011, PloS one.
[33] S. Kwon,et al. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. , 2011, Gastroenterology.
[34] Chris Sander,et al. MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors , 2011, PloS one.
[35] S. Abdulkadir,et al. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53 , 2011, Oncogene.